Recently, we developed WT1-antigen-expressing aAVC (aAVC-WT1) therapy for relapsed and refractory AML patients [66] and completed the first human clinical trial of aAVC-WT1 therapy (Table 1). This evidence concerns the gene WT1 and acute myeloid leukemia.